Dr. John Thoms, MD MSc FRCPC
Assistant Professor of Oncology, Memorial University of Newfoundland
Radiation Oncology Consultant - Eastern Health
Prostate cancer carcinogenesis, biomarkers of treatment response, novel clinical trials, radiation therapy
Prostate cancer is the most common cancer in men. Radiation therapy is a common and accepted standard treatment option for men with prostate cancer. Yet, a large portion of men still fail radiation therapy. Additional biomarkers that could denote aggressive disease could effectively triage patients to more individualized management. The primary research interests of my lab pertains to biomarkers of radiotherapy response for prostate cancer; proteomic technologies, novel therapeutics and novel clinical trials.